Dr. Reddy’s Laboratories has received approval for proposal of sale of its investment in the Wholly-owned Subsidiary — Imperial Credit (Imperial), a Non- Banking Finance Company (NBFC), subject to applicable regulatory approvals. Imperial Credit is not a material subsidiary of the company. Sale of investment is subject to approval of the Reserve Bank of India … Read more
Dr. Reddy’s Laboratories’ wholly owned subsidiary — Aurigene Discovery Technologies (Aurigene) and Olema Pharmaceuticals, Inc (Olema) have entered into exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target. Under the terms of the agreement, Olema will make an upfront licensing payment of $8 million for rights … Read more
Dr. Reddy’s Laboratories has received final approval for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of REVLIMID (lenalidomide) Capsules, from the U.S. Food and Drug Administration (USFDA). … Read more
Dr Reddy’s Laboratories is working on the development of new treatment options for COVID-19 patients which it aims to launch over the next few months while ensuring uninterrupted supplies of its existing range of products for the infectious disease in the market. The company has already launched Sputnik V vaccine while partnering various organisations, including … Read more
